Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Gut Microbiome Profiles in Patients With Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial With Ozone OzoParQT (NCT06706544).

NCT06799351 is registered in ClinicalTrials.gov with Bernardino Clavo, MD, PhD as lead sponsor.

NCT NCT06799351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06799351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Gut Microbiome Profiles in Patients With Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial With Ozone OzoParQT (NCT06706544).
Lead sponsor
Bernardino Clavo, MD, PhD
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 7, 2025
Completion date
March 31, 2030
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced peripheral neuropathy (cipn), numbness, paresthesia, tingling